39 results on '"Khalif IL"'
Search Results
2. Long-term results of medical treatment in patients with a severe attack of ulcerative colitis
- Author
-
Nanaeva Ba, Khalif Il, A. O. Golovenko, and O. V. Golovenko
- Subjects
Adult ,Male ,History ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Azathioprine ,Maintenance therapy ,Recurrence ,Internal medicine ,Humans ,Medicine ,In patient ,Colectomy ,Medical treatment ,business.industry ,Age Factors ,General Medicine ,Middle Aged ,medicine.disease ,Ulcerative colitis ,Infliximab ,Treatment Outcome ,Acute Disease ,Prednisolone ,Colitis, Ulcerative ,Female ,Family Practice ,business ,Follow-Up Studies ,medicine.drug - Abstract
To assess the long-term result of medical treatment in patients with a severe attack (SA) of ulcerative colitis (UC).The course of UC was analyzed in 56 patients who were accessible by telephone contact and consecutively recruited for a year after therapy for a SA of UC. All the patients were stated to have a SA of UC according to the Truelove-Witts' criteria; they received therapy with intravenous glucocorticosteroids (GCS) (prednisolone 2 mg/kg) along with anti-recurrence therapy with mesalasine (5-ASA) or azathioprine (AZA). Ten (17.9%) GCS-resistant patients were given infliximab (INF) (5 mg/ kg), followed by its maintenance infusions. Anti-recurrence therapy using 5-ASA, AZA, and INF was performed in 33 (58.9%), 13 (23.2%), and 10 (17.9%) patients, respectively.During one year, 14 (25%) patients continued to be in clinical remission on maintenance therapy or to have attacks stopped without using GCS, immunosuppressive agents, or INF (a satisfactory response group). Colectomy was carried out in 23 (41.1%) patients; due to recurrent UC when decreasing the dose of GCS, 5 (8.9%) patients continued to take the latter during a year. A GCS cycle was repeated in 3 patients who had received AZA (the basic therapy was not corrected) and 11 patients who had taken 5-ASA. The prognostic factors for a long-term result of medical therapy included the choice of AZA as an anti-recurrent drug (57.1 and 11.9% in the satisfactory and poor treatment outcome groups, respectively; p = 0.004) and patient age (34.4 and 42.8 years, respectively; p = 0.0357).During 1 year after a SA of UC, indications for colectomy and repeated GCS use occurred in 41 and 34% of the patients, respectively. The long-term efficiency of medical therapy for a SA of UC declines with advancing age. The use of AZA as an anti-recurrence agent after termination of GCS intake increases the probability of long-term clinical response.Цель исследования. Оценить долгосрочный результат консервативного лечения больных с тяжелым обострением (ТО) язвенного колита (ЯК). Материалы и методы. Проанализировали течение ЯК у 56 доступных для телефонного контакта последовательно набранных пациентов в течение года после проведения терапии ТО ЯК. У всех пациентов констатировано ТО ЯК по критериям Truelove-Witts и проведена терапия внутривенными глюкокортикостероидами - ГКС (преднизолон 2 мг/кг) с назначением противорецидивной терапии месалазином (5-АСК) или азатиоприном (АЗА). Резистентным к ГКС 10 (17,9%) пациентам назначен инфликсимаб - ИНФ (5 мг/кг) с проведением последующих поддерживающих инфузий. Противорецидивную терапию проводили 33 (58,9%) пациентам 5-АСК, 13 (23,2%) АЗА, 10 (17,9%) ИНФ. Результаты. В течение 1 года у 14 (25%) больных сохранялась клиническая ремиссия на фоне поддерживающей терапии или отмечались обострения, купированные без применения ГКС, иммуносупрессоров или ИНФ (группа с удовлетворительным ответом). Колэктомия выполнена 23 (41,1%) больным, 5 (8,9%) пациентов в связи с рецидивом ЯК при снижении дозы ГКС продолжили прием ГКС в течение 1 года. Повторный курс ГКС проведен 3 пациентам, получавшим АЗА (базисная терапия не корректировалась), и 11 больным, получавшим 5-АСК. К прогностическим факторам долгосрочного результата консервативной терапии отнесены выбор АЗА в качестве противорецидивного препарата (57,1 и 11,9% в группах с удовлетворительным и неудовлетворительным исходом лечения соответственно; р=0,004) и возраст больных (34,4 и 42,8 года соответственно; р=0,0357). Заключение. В течение 1 года после ТО ЯК у 41% больных возникают показания к колэктомии, у 34% - к повторному применению ГКС. Долгосрочная эффективность консервативной терапии ТО ЯК уменьшается с увеличением возраста. Применение АЗА в качестве противорецидивного средства после окончания приема ГКС повышает вероятность долгосрочного клинического ответа.
- Published
- 2015
3. A Global Perspective on Irritable Bowel Syndrome
- Author
-
Kok Ann Gwee, Joaquim Prado P Moraes-Filho, Magnus Simrén, Max Schmulson, Lucinda A. Harris, Amy E. Foxx-Orenstein, Christian Tzeuton, Carolina Olano, Richard H. Hunt, Hussein Abdel-Hamid, Michel Delvaux, Francisco Guarner, Roberto De Giorgio, Greger Lindberg, Eamonn Martin Quigley, Lawrence R. Schiller, I. Khalif, Douglas Drossman, A. Pali S Hungin, Guy Boeckxstaens, Giovanni Barbara, Shobna Bhatia, Wolfgang Kruis, John Kellow, Quigley EM., Abdel-Hamid H., Barbara G., Bhatia SJ, Boeckxstaens G., De Giorgio R., Delvaux M., Drossman DA., Foxx-Orenstein AE., Guarner F., Gwee KA, Harris LA., Hungin AP., Hunt RH., Kellow JE., Khalif IL., Kruis W., Lindberg G., Olano C., Moraes-Filho JP., Schiller LR., Schmulson M., Simrén M., and Tzeuton C.
- Subjects
Adult ,Male ,COMORBIDITY ,CONSTIPATION ,DIARRHEA ,Rome criteria ,EPIDEMIOLOGY ,postinfectious irritable bowel syndrome ,irritable bowel syndrome ,NATURAL HISTORY ,medicine.medical_specialty ,Adolescent ,Alternative medicine ,MEDLINE ,Global Health ,Gastroenterology ,NO ,Young Adult ,Internal medicine ,Epidemiology ,Prevalence ,medicine ,Global health ,Humans ,Child ,Irritable bowel syndrome ,Aged ,Aged, 80 and over ,business.industry ,International comparisons ,Middle Aged ,medicine.disease ,Comorbidity ,Natural history ,Female ,business - Abstract
Irritable bowel syndrome (IBS) is common in western Europe and North America, and many aspects of its epidemiology, risk factors, and natural history have been described in these regions. Recent data suggest, however, that IBS is also common in the rest of the world and there has been some evidence to suggest some differences in demographics and presenting features between IBS in the west and as it is experienced elsewhere. The World Gastroenterology Organization, therefore, established a Task Force comprising experts on the topic from all parts of the world to examine IBS from a global perspective. IBS does, indeed, seem to be common worldwide though with some significant variations in prevalence rates between regions and countries and there may well be some potentially interesting variations in presenting symptoms and sex distribution. The global map of IBS is far from complete; community-based prevalence data is not available from many areas. Furthermore, while some general trends are evident in terms of IBS impact and demographics, international comparisons are hampered by differences in diagnostic criteria, study location and methodology; several important unanswered questions have been identified that should form the basis for future collaborative research and have the potential to shed light on this challenging disorder. © 2012 by Lippincott Williams & Wilkins.
- Published
- 2012
4. [Irritable bowel syndrome in the Russian Federation: results of the ROMERUS multicenter observational study].
- Author
-
Maev IV, Okhlobystina OZ, Khalif IL, and Andreev DN
- Subjects
- Humans, Male, Female, Adult, Quality of Life, Constipation, Diarrhea diagnosis, Abdominal Pain diagnosis, Abdominal Pain epidemiology, Abdominal Pain etiology, Surveys and Questionnaires, Russia epidemiology, Irritable Bowel Syndrome diagnosis, Irritable Bowel Syndrome epidemiology, Irritable Bowel Syndrome complications
- Abstract
Background: Irritable bowel syndrome (IBS) is one of the most common functional disorders of the gastrointestinal tract. According to Russian guidelines, a standard examination using laboratory and instrumental evaluation methods, including colonoscopy, should be performed to establish the diagnosis of IBS., Aim: To characterize the Russian population of IBS patients., Materials and Methods: A multicenter observational prospective study ROMERUS was conducted at 35 clinical centers in the Russian Federation. The study included male and female patients aged 18 to 50 with a diagnosis of IBS based on the Rome IV criteria, with no signs of structural gastrointestinal disease. The follow-up duration was 6 months and included three patients' visits to the study site. During the study, data were collected on patients' demographic and clinical characteristics, medical history, and drug therapy. The secondary parameters included the assessment of the proportion of patients with a diagnosis of IBS confirmed by a standard examination among all patients meeting the Rome IV criteria, the evaluation of the change over time of the IBS symptoms, quality of life (QoL), and adherence to therapy. Characterization of the population was performed using descriptive statistics methods. The standard examination results were presented as the percentage of patients with IBS confirmed by the standard examination among all patients meeting the Rome IV criteria, with a two-sided 95% confidence interval., Results: The study included 1004 patients with a diagnosis of IBS according to the Rome IV criteria, with 790 (78.7%) patients included in the final analysis. The mean age of patients was 34.0±7.5 years; they were predominantly female (70.4%), Caucasian (99.4%), married (55.1%), urban residents (97.5%) with higher education (64.5%) and a permanent position (74.9%). Patients enrolled in the study have low physical activity and lack a healthy diet. The smoking rate was 26.3%. IBS symptoms with predominant constipation (IBS-C) were observed in 28.1% of patients; 28.9% had IBS with predominant diarrhea (IBS-D), 11.9% had mixed-type IBS, and 31.1% had non-classified IBS. The main IBS symptoms were pain (99.7%), abdominal distension (71.1%), and fullness (36.8%). Biliary tract dysfunction (18.9%) and gastritis (17.2%) were the most frequently reported comorbidities. Prior to enrollment, 28% of patients received drug therapy. The most commonly prescribed drug during the study was mebeverine (54.1%). At 6 months of follow-up, there was a significant reduction of abdominal pain, bloating, and distention, and a twofold reduction in the incidence of constipation and diarrhea in the subgroups of patients with IBS-C and IBS-D, respectively. The overall QoL score measured by the IBS-QoL questionnaire increased from 83.0 to 95.2 points ( p <0.05) during the study. In the overall assessment of their condition, 69.6% of patients noted no symptoms and 25.3% reported marked improvement, 35% were asymptomatic according to the physician's overall assessment of the patient's condition, and 51.8% showed significant improvement., Conclusion: IBS patients in the Russian Federation were characterized. The diagnosis of IBS, established following the Rome IV criteria, is confirmed by the results of a standard examination in 96.3% of patients. The Rome IV criteria for the IBS diagnosis make it possible to establish a diagnosis with a probability of 94.7%. For 6 months of follow-up, there was a clinical improvement with a decrease in the severity of symptoms and a QoL improvement.
- Published
- 2023
- Full Text
- View/download PDF
5. Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients.
- Author
-
Obraztsov IV, Shirokikh KE, Obraztsova OI, Shapina MV, Wang MH, and Khalif IL
- Subjects
- Adult, Colitis, Ulcerative drug therapy, Female, Follow-Up Studies, Humans, Male, Prognosis, Biomarkers blood, Colitis, Ulcerative blood, Cytokines blood, Infliximab therapeutic use, Tumor Necrosis Factor Inhibitors therapeutic use, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Background and Aims: Ulcerative colitis (UC) is a form of inflammatory bowel disease, and antibodies against tumor necrosis factor (anti-TNF) are used for treatment. Many patients are refractory or lose response to anti-TNF, and predicting response would be an extremely valuable clinical tool. Unlike most biomarkers, cytokines directly mediate inflammation, and their measurement may predict the likelihood of response or no response., Methods: Serum samples were obtained from 49 UC patients before infliximab infusions, and levels of 17 cytokines were measured using a multiplex assay. The Fisher linear discriminant analysis (FLDA) was applied to the cytokine values to predict which patients would respond to infliximab. "Response" was defined as clinical remission after the third infusion, and "no response" was defined as lack of remission after the third infusion., Results: The Fisher linear discriminant analysis model identified a subset of seven predictor cytokines: TNF-α, IL-12, IL-8, IL-2, IL-5, IL1-β, and IFN-γ. The obtained canonical coefficients enabled to calculate discriminant scores as linear combinations of the cytokines; model classified thepatients as responders and nonresponders with a sensitivity of 84.2% and a specificity of 93.3%. Overall, the yield of the FLDA model was 89.8% of the total 49 patients., Conclusions: An unbiased, statistically derived, predictive model based on measurement of serum cytokines before therapy may predict a positive or negative outcome from the administration of anti-TNF to UC patients. Because accurately measuring cytokines is simple and inexpensive, the model may be a valuable new tool to complement other laboratory parameters used in the management of IBD patients., (© 2018 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
6. Genetic diversity of Escherichia coli in gut microbiota of patients with Crohn's disease discovered using metagenomic and genomic analyses.
- Author
-
Tyakht AV, Manolov AI, Kanygina AV, Ischenko DS, Kovarsky BA, Popenko AS, Pavlenko AV, Elizarova AV, Rakitina DV, Baikova JP, Ladygina VG, Kostryukova ES, Karpova IY, Semashko TA, Larin AK, Grigoryeva TV, Sinyagina MN, Malanin SY, Shcherbakov PL, Kharitonova AY, Khalif IL, Shapina MV, Maev IV, Andreev DN, Belousova EA, Buzunova YM, Alexeev DG, and Govorun VM
- Subjects
- Cluster Analysis, Crohn Disease microbiology, Escherichia coli isolation & purification, Feces microbiology, Genome, Bacterial, Humans, Intestinal Mucosa microbiology, Crohn Disease pathology, Escherichia coli genetics, Gastrointestinal Microbiome, Genetic Variation, Metagenomics methods
- Abstract
Background: Crohn's disease is associated with gut dysbiosis. Independent studies have shown an increase in the abundance of certain bacterial species, particularly Escherichia coli with the adherent-invasive pathotype, in the gut. The role of these species in this disease needs to be elucidated., Methods: We performed a metagenomic study investigating the gut microbiota of patients with Crohn's disease. A metagenomic reconstruction of the consensus genome content of the species was used to assess the genetic variability., Results: The abnormal shifts in the microbial community structures in Crohn's disease were heterogeneous among the patients. The metagenomic data suggested the existence of multiple E. coli strains within individual patients. We discovered that the genetic diversity of the species was high and that only a few samples manifested similarity to the adherent-invasive varieties. The other species demonstrated genetic diversity comparable to that observed in the healthy subjects. Our results were supported by a comparison of the sequenced genomes of isolates from the same microbiota samples and a meta-analysis of published gut metagenomes., Conclusions: The genomic diversity of Crohn's disease-associated E. coli within and among the patients paves the way towards an understanding of the microbial mechanisms underlying the onset and progression of the Crohn's disease and the development of new strategies for the prevention and treatment of this disease.
- Published
- 2018
- Full Text
- View/download PDF
7. Certolizumab pegol in treatment of Crohn's disease with perianal lesions.
- Author
-
Khalif IL, Nanaeva BA, Shapina MV, and Vardanyan AV
- Subjects
- Humans, Immunoglobulin Fab Fragments, Polyethylene Glycols, Quality of Life, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Certolizumab Pegol therapeutic use, Crohn Disease drug therapy
- Abstract
Aim: To assess the effectiveness of conservative treatment of Crohn's disease (CD) with perianal lesions., Materials and Methods: The study included 20 patients with CD with perianal fistulae. Prior to the start of conservative therapy, 7 patients underwent fistulae drainage with setton placement. During the study, all patients received therapy with certolizumab pegol (CP) for a year. At the time of treatment initiation and after 12 months, the CD activity index, the quality of life according to IBDQ questionnaires and the perianal Crohn's disease activity index (PCDAI) were assessed., Results: After a year of CP therapy, clinical remission was achieved in 8 (40%) patients, endoscopic remission in 7 (35%) patients, fistula closure in 6 (30%) patients. There was also a decrease in the PCDAI with the average score 3.6 points compared to 9.3 points (p˂0.05) prior to the treatment. An improvement in the quality of life of patients was also established, the average quality of life index was 182,2 points compared to 156,0 points (p˂0.05) prior to the treatment., Conclusion: This study showed that CP therapy is effective in treatment of CD with perianal lesions.
- Published
- 2018
- Full Text
- View/download PDF
8. Genome analysis of E. coli isolated from Crohn's disease patients.
- Author
-
Rakitina DV, Manolov AI, Kanygina AV, Garushyants SK, Baikova JP, Alexeev DG, Ladygina VG, Kostryukova ES, Larin AK, Semashko TA, Karpova IY, Babenko VV, Ismagilova RK, Malanin SY, Gelfand MS, Ilina EN, Gorodnichev RB, Lisitsyna ES, Aleshkin GI, Scherbakov PL, Khalif IL, Shapina MV, Maev IV, Andreev DN, and Govorun VM
- Subjects
- Adult, Anti-Bacterial Agents pharmacology, Bacteriocins biosynthesis, Drug Resistance, Bacterial genetics, Escherichia coli drug effects, Escherichia coli metabolism, Female, Genetic Variation, Humans, Male, Middle Aged, Phylogeny, Young Adult, Crohn Disease microbiology, Escherichia coli genetics, Escherichia coli physiology, Genomics
- Abstract
Background: Escherichia coli (E. coli) has been increasingly implicated in the pathogenesis of Crohn's disease (CD). The phylogeny of E. coli isolated from Crohn's disease patients (CDEC) was controversial, and while genotyping results suggested heterogeneity, the sequenced strains of E. coli from CD patients were closely related., Results: We performed the shotgun genome sequencing of 28 E. coli isolates from ten CD patients and compared genomes from these isolates with already published genomes of CD strains and other pathogenic and non-pathogenic strains. CDEC was shown to belong to A, B1, B2 and D phylogenetic groups. The plasmid and several operons from the reference CD-associated E. coli strain LF82 were demonstrated to be more often present in CDEC genomes belonging to different phylogenetic groups than in genomes of commensal strains. The operons include carbon-source induced invasion GimA island, prophage I, iron uptake operons I and II, capsular assembly pathogenetic island IV and propanediol and galactitol utilization operons., Conclusions: Our findings suggest that CDEC are phylogenetically diverse. However, some strains isolated from independent sources possess highly similar chromosome or plasmids. Though no CD-specific genes or functional domains were present in all CD-associated strains, some genes and operons are more often found in the genomes of CDEC than in commensal E. coli. They are principally linked to gut colonization and utilization of propanediol and other sugar alcohols.
- Published
- 2017
- Full Text
- View/download PDF
9. Inflammatory bowel disease treatment in Eastern Europe: current status, challenges and needs.
- Author
-
Khalif IL and Shapina MV
- Subjects
- Disability Evaluation, Europe, Eastern epidemiology, Humans, Incidence, Inflammatory Bowel Diseases epidemiology, Needs Assessment, Patient Education as Topic, Prospective Studies, Health Services Accessibility standards, Inflammatory Bowel Diseases therapy, Practice Patterns, Physicians' statistics & numerical data, Quality Improvement standards, Quality of Health Care standards
- Abstract
Purpose of Review: To analyze the available studies of course, diagnosis and treatment of Inflammatory bowel disease (IBD) in Eastern Europe., Recent Findings: According to published data, full epidemiological studies were conducted only in Czech Republic, Estonia, Hungary and Romania. Russia was recently included in the EpiCom study, although only Moscow region data were provided., Summary: We summarize previously published and unpublished data on the epidemiology, IBD diagnosis and treatment in Eastern Europe. In addition, changes during several years are presented. These data show that IBD epidemiology in Eastern Europe corresponds to the previously known patterns, and that the quality of IBD health care has improved in the last several years.
- Published
- 2017
- Full Text
- View/download PDF
10. [All-Russian Consensus on Diagnosis and Treatment of Celiac Disease in Children and Adults].
- Author
-
Parfenov AI, Bykova SV, Sabel'nikova EA, Maev IV, Baranov AA, Bakulin IG, Krums LM, Bel'mer SV, Borovik TE, Zakharova IN, Dmitrieva YA, Roslavtseva EA, Kornienko EA, Khavkin AI, Potapov AS, Revnova MO, Mukhina YG, Shcherbakov PL, Fedorov ED, Belousova EA, Khalif IL, Khomeriki SG, Rotin DL, Vorob'eva NG, Pivnik AV, Gudkova RB, Chernin VV, Vokhmyanina NV, Pukhlikova TV, Degtyarev DA, Damulin IV, Mkrtumyan AM, Dzhulai GS, Tetruashvili NK, Baranovsky AY, Nazarenko LI, Kharitonov AG, Loranskaya ID, Saifutdinov RG, Livzan MA, Abramov DA, Osipenko MF, Oreshko LV, Tkachenko EI, Sitkin SI, and Efremov LI
- Subjects
- Adult, Child, Evidence-Based Medicine, Humans, Russia, Celiac Disease classification, Celiac Disease diagnosis, Celiac Disease therapy, Disease Management
- Abstract
The paper presents the All-Russian consensus on the diagnosis and treatment of celiac disease in children and adults, which has been elaborated by leading experts, such as gastroenterologists and pediatricians of Russia on the basis of the existing Russian and international guidelines. The consensus approved at the 42nd Annual Scientific Session of the Central Research Institute of Gastroenterology on Principles of Evidence-Based Medicine into Clinical Practice (March 2-3, 2016). The consensus is intended for practitioners engaged in the management and treatment of patients with celiac disease. Evidence for the main provisions of the consensus was sought in electronic databases. In making recommendations, the main source was the publications included in the Cochrane Library, EMBASE, MEDLINE, and PubMed. The search depth was 10 years. Recommendations in the preliminary version were reviewed by independent experts. Voting was done by the Delphic polling system.
- Published
- 2017
- Full Text
- View/download PDF
11. CANCERPREVENTIVE IN ULCERATIVE COLITIS.
- Author
-
Podolskaya DV, Shapina MV, and Khalif IL
- Subjects
- Animals, Colitis, Ulcerative metabolism, Colitis, Ulcerative pathology, Colorectal Neoplasms metabolism, Colorectal Neoplasms pathology, Humans, Colitis, Ulcerative drug therapy, Colorectal Neoplasms prevention & control, Immunologic Factors therapeutic use, Mesalamine therapeutic use, Ursodeoxycholic Acid therapeutic use
- Abstract
Colorectal cancer (CRC) is an actual problem today And it occurs 6 times more frequently in patients with inflammatory bowel diseases (IBD) than in healthy population. CRC in IBD patients is more aggressive and needs total colectomy, which leads to permanent disability That is why canceroprevention is one of the key goals of IBD treatment. The aim of this review is to overview actual pathogenesis pathways of CRC in IBD and methods of chemoprevention. In this review we describe risk factors of CRC, which can be summarized as aggressive disease and chronic inflammation and are based on pathogenesis of CRC. That is the reason why methods of chemoprevention needs to influence on inflammation and other pathogenesis pathways. The role of such classes of medication as non-steroidal anti-inflammatory drugs, 5-aminosalicylic acid, immunomodulators, ursodeoxycholic acid in canceroprevention in RD patients are described in this review.
- Published
- 2016
12. [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis].
- Author
-
Khalif IL, Nanaeva BA, Golovenko AO, and Golovenko OV
- Subjects
- Acute Disease, Adult, Age Factors, Female, Follow-Up Studies, Humans, Male, Middle Aged, Recurrence, Treatment Outcome, Colitis, Ulcerative drug therapy
- Abstract
Aim: To assess the long-term result of medical treatment in patients with a severe attack (SA) of ulcerative colitis (UC)., Subjects and Methods: The course of UC was analyzed in 56 patients who were accessible by telephone contact and consecutively recruited for a year after therapy for a SA of UC. All the patients were stated to have a SA of UC according to the Truelove-Witts' criteria; they received therapy with intravenous glucocorticosteroids (GCS) (prednisolone 2 mg/kg) along with anti-recurrence therapy with mesalasine (5-ASA) or azathioprine (AZA). Ten (17.9%) GCS-resistant patients were given infliximab (INF) (5 mg/ kg), followed by its maintenance infusions. Anti-recurrence therapy using 5-ASA, AZA, and INF was performed in 33 (58.9%), 13 (23.2%), and 10 (17.9%) patients, respectively., Results: During one year, 14 (25%) patients continued to be in clinical remission on maintenance therapy or to have attacks stopped without using GCS, immunosuppressive agents, or INF (a satisfactory response group). Colectomy was carried out in 23 (41.1%) patients; due to recurrent UC when decreasing the dose of GCS, 5 (8.9%) patients continued to take the latter during a year. A GCS cycle was repeated in 3 patients who had received AZA (the basic therapy was not corrected) and 11 patients who had taken 5-ASA. The prognostic factors for a long-term result of medical therapy included the choice of AZA as an anti-recurrent drug (57.1 and 11.9% in the satisfactory and poor treatment outcome groups, respectively; p = 0.004) and patient age (34.4 and 42.8 years, respectively; p = 0.0357)., Conclusion: During 1 year after a SA of UC, indications for colectomy and repeated GCS use occurred in 41 and 34% of the patients, respectively. The long-term efficiency of medical therapy for a SA of UC declines with advancing age. The use of AZA as an anti-recurrence agent after termination of GCS intake increases the probability of long-term clinical response.
- Published
- 2015
- Full Text
- View/download PDF
13. [Efficiency of tacrolimus therapy for perianal Crohn's disease].
- Author
-
Nanaeva BA, Vardanyan AV, and Khalif IL
- Subjects
- Adult, Anal Canal, Colitis diagnosis, Crohn Disease diagnosis, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Immunosuppressive Agents administration & dosage, Male, Middle Aged, Prospective Studies, Treatment Outcome, Young Adult, Colitis drug therapy, Crohn Disease drug therapy, Tacrolimus administration & dosage
- Abstract
Aim: To determine the efficacy of 0.1% tacrolimus ointment in patients with perianal Crohn's disease (CD)., Subjects and Methods: This prospective randomized trial enrolled 20 patients with perianal CD as anal fissures and rectal fistulas. The inclusion criteria were rectovaginal or extrasphincteric fistulas and purulent leakages. A study group comprised 11 patients, including 9 with anal fissures and 2 with fistulas. A control group included 9 patients, including 8 with fissures and 1 with fistulas. The study group received systemic therapy with azathioprine 2 mg/kg/day and tacrolimus ointment 2 mg/day; the control group had systemic therapy with azathioprine 2 mg/kg/day, hormone ointment 1 mg/day, and metronidazole suppositories 250 mg/day. Control examination and perianal CD activity index (PCDAI) determination were done 6 and 12 weeks after therapy initiation., Results: At 6 weeks after beginning the study, local examination revealed the signs of anal fissure epithelialization in 5 (45.5%) of the 11 patients in the study group and in 3 (33.3%) of the 9 patients in the control one. At 12 weeks, fissure epithelialization and fistula obliteration were stated in 6 (54%) patients in the study group and in 3 (33%) of the 9 patients in the control group. At 12 weeks, PCDAI in the study and control groups was 2.00 and 4.44 scores (p = 0.01)., Conclusion: The findings suggest that topical 0.1% tacrolimus ointment versus antibacterial suppositories and hormone ointments is effective in treating patients with perianal CD. Topical 0.1% tacrolimus ointment therapy caused a reduction in PCDAI.
- Published
- 2015
- Full Text
- View/download PDF
14. [The probiotics effectiveness in the therapy of inflammatory bowel diseases].
- Author
-
Khalif IL, Golovenko AO, Dikshteĭn II, and Belous SS
- Subjects
- Humans, Inflammatory Bowel Diseases pathology, Inflammatory Bowel Diseases physiopathology, Inflammatory Bowel Diseases therapy, Probiotics therapeutic use
- Published
- 2013
15. [Role of rifaximin in correction of IBS-like symptoms in patients with inflammatory bowel disease].
- Author
-
Belous SS, Khalif IL, and Golovenko OV
- Subjects
- Abdominal Pain drug therapy, Abdominal Pain pathology, Abdominal Pain physiopathology, Humans, Intestinal Mucosa pathology, Intestinal Mucosa physiopathology, Rifaximin, Gastrointestinal Agents therapeutic use, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases pathology, Inflammatory Bowel Diseases physiopathology, Rifamycins therapeutic use
- Abstract
One of the important problems in the treatment of patients with inflammatory bowel disease are the persistent complaints of pain, abdominal distention, frequent stools, excretion of mucus with faeces with the presence of endoscopic or roentgenologic remission in the damaged parts of gastrointestinal tract. In this review we describe possible causes of such complaints and some methods of their therapeutic correction.
- Published
- 2013
16. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome.
- Author
-
Quigley EM, Abdel-Hamid H, Barbara G, Bhatia SJ, Boeckxstaens G, De Giorgio R, Delvaux M, Drossman DA, Foxx-Orenstein AE, Guarner F, Gwee KA, Harris LA, Hungin AP, Hunt RH, Kellow JE, Khalif IL, Kruis W, Lindberg G, Olano C, Moraes-Filho JP, Schiller LR, Schmulson M, Simrén M, and Tzeuton C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Female, Humans, Male, Middle Aged, Prevalence, Young Adult, Global Health, Irritable Bowel Syndrome diagnosis, Irritable Bowel Syndrome epidemiology, Irritable Bowel Syndrome pathology, Irritable Bowel Syndrome psychology
- Abstract
Irritable bowel syndrome (IBS) is common in western Europe and North America, and many aspects of its epidemiology, risk factors, and natural history have been described in these regions. Recent data suggest, however, that IBS is also common in the rest of the world and there has been some evidence to suggest some differences in demographics and presenting features between IBS in the west and as it is experienced elsewhere. The World Gastroenterology Organization, therefore, established a Task Force comprising experts on the topic from all parts of the world to examine IBS from a global perspective. IBS does, indeed, seem to be common worldwide though with some significant variations in prevalence rates between regions and countries and there may well be some potentially interesting variations in presenting symptoms and sex distribution. The global map of IBS is far from complete; community-based prevalence data is not available from many areas. Furthermore, while some general trends are evident in terms of IBS impact and demographics, international comparisons are hampered by differences in diagnostic criteria, study location and methodology; several important unanswered questions have been identified that should form the basis for future collaborative research and have the potential to shed light on this challenging disorder.
- Published
- 2012
- Full Text
- View/download PDF
17. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
- Author
-
Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, and Gasche C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anemia, Iron-Deficiency blood, Comorbidity, Dose-Response Relationship, Drug, Female, Ferric Compounds administration & dosage, Ferric Compounds adverse effects, Ferric Oxide, Saccharated, Glucaric Acid, Hemoglobins metabolism, Humans, Inflammatory Bowel Diseases blood, Infusions, Intravenous, Male, Maltose administration & dosage, Maltose adverse effects, Maltose therapeutic use, Middle Aged, Outcome Assessment, Health Care, Treatment Outcome, Young Adult, Anemia, Iron-Deficiency drug therapy, Anemia, Iron-Deficiency epidemiology, Ferric Compounds therapeutic use, Inflammatory Bowel Diseases drug therapy, Inflammatory Bowel Diseases epidemiology, Maltose analogs & derivatives
- Abstract
Background & Aims: Iron deficiency anemia (IDA) is common in chronic diseases and intravenous iron is an effective and recommended treatment. However, dose calculations and inconvenient administration may affect compliance and efficacy. We compared the efficacy and safety of a novel fixed-dose ferric carboxymaltose regimen (FCM) with individually calculated iron sucrose (IS) doses in patients with inflammatory bowel disease (IBD) and IDA., Methods: This randomized, controlled, open-label, multicenter study included 485 patients with IDA (ferritin <100 μg/L, hemoglobin [Hb] 7-12 g/dL [female] or 7-13 g/dL [male]) and mild-to-moderate or quiescent IBD at 88 hospitals and clinics in 14 countries. Patients received either FCM in a maximum of 3 infusions of 1000 or 500 mg iron, or Ganzoni-calculated IS dosages in up to 11 infusions of 200 mg iron. Primary end point was Hb response (Hb increase ≥ 2 g/dL); secondary end points included anemia resolution and iron status normalization by week 12., Results: The results of 240 FCM-treated and 235 IS-treated patients were analyzed. More patients with FCM than IS achieved Hb response (150 [65.8%] vs 118 [53.6%]; 12.2% difference, P = .004) or Hb normalization (166 [72.8%] vs 136 [61.8%]; 11.0% difference, P = .015). Both treatments improved quality of life scores by week 12. Study drugs were well tolerated and drug-related adverse events were in line with drug-specific clinical experience. Deviations from scheduled total iron dosages were more frequent in the IS group., Conclusions: The simpler FCM-based dosing regimen showed better efficacy and compliance, as well as a good safety profile, compared with the Ganzoni-calculated IS dose regimen., (Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
18. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics).
- Author
-
Khalif IL, Quigley EM, Makarchuk PA, Golovenko OV, Podmarenkova LF, and Dzhanayev YA
- Subjects
- Administration, Oral, Administration, Rectal, Adult, Butylscopolammonium Bromide administration & dosage, Calcium Gluconate administration & dosage, Calendula, Diarrhea drug therapy, Diarrhea etiology, Diarrhea physiopathology, Female, Humans, Irritable Bowel Syndrome complications, Irritable Bowel Syndrome physiopathology, Male, Pain etiology, Pain physiopathology, Pain Measurement, Papaverine administration & dosage, Papaverine analogs & derivatives, Plant Preparations administration & dosage, Severity of Illness Index, Suppositories, Tablets, Treatment Outcome, Young Adult, Colon, Sigmoid innervation, Gastrointestinal Motility drug effects, Irritable Bowel Syndrome drug therapy, Motor Neurons, Pain drug therapy, Parasympatholytics administration & dosage, Rectum innervation, Sensory Receptor Cells
- Abstract
Aim: to evaluate and correlate the symptomatic, motor and sensory responses to two widely used categories of spasmolytic agents in irritable bowel syndrome (IBS)., Methods: 118 patients with IBS, diagnosed by Rome II criteria and 45 healthy individuals were studied. In the IBS subjects, pain severity, as well as the sensory response to rectal balloon distention and rectal and sigmoid motility, were studied at baseline and after two weeks therapy with either oral buscopan (20 mg three times a day, n=37), a buscopan suppository (30 mg once daily, n=21), oral drotaverine (80 mg three times a day, n=30), calcium gluconate tablets (one three times a day, n=16) as a control for oral agents, or calendula suppository (once daily, n=14) as a control for those who received a suppository., Results: Buscopan, whether administered as a tablet or a suppository, produced a significant reduction in pain scores among IBS patients with predominant diarrhea. No significant differences were evident among other IBS subgroups or in response to drotaverine. None of the interventions had any effect on any of the parameters of rectal or sigmoid motility studied. However, both buscopan and drotaverine led to a significant augmentation of the rectal threshold for discomfort/pain among IBS subjects with predominant diarrhea [21.78 + or - 2.8 vs 39.60 + or - 2.4 (p<0.05), 20.5 + or - 2,8 vs 36.84 + or - 3.8 (p<0.05) and 22.18 + or - 2.8 vs 36.9 + or - 2.42 (p<0.05) for oral buscopan, rectal buscopan and oral drotaverine, respectively]., Conclusion: We conclude that the clinical benefits of supposed spasmolytic (anti-spasmodic) agents may relate more to effects on visceral sensation than motility.
- Published
- 2009
19. [The clinicomorphological characterization of segmental lesion in ulcerous colitis].
- Author
-
Vorob'ev GI, Khalif IL, Malakhova NS, Kapuller LL, Vasil'chenko AV, Mikhaĭlova TL, and Golovenko OV
- Subjects
- Adolescent, Adult, Aged, Biopsy, Colitis, Ulcerative drug therapy, Colonoscopy, Female, Follow-Up Studies, Glucocorticoids therapeutic use, Humans, Male, Middle Aged, Prednisolone therapeutic use, Retrospective Studies, Severity of Illness Index, Cecum pathology, Colitis, Ulcerative pathology, Colon pathology
- Abstract
The authors analyzed the clinical picture in 18 patients with distal lesion of the colon and an inflammatory focus in the cecum (segmentary lesion), and five patients with distal lesion of the colon revealed with endoscopy and pathomorphological signs of inflammation in visually intact cecum. The analysis shows that in a range of cases the extent of lesion in ulcerous colitis (UC) cannot be determined correctly with colonoscopy. An apparent segmentary character of lesion (inflammation in the distal colon and an inflammatory focus in the cecum) is an additional criterion of unfavorable prognosis of transformation into disseminated UC forms. Such patients need application of the same treatment regimens as in patients with disseminated UC forms.
- Published
- 2007
20. Alterations in the colonic flora and intestinal permeability and evidence of immune activation in chronic constipation.
- Author
-
Khalif IL, Quigley EM, Konovitch EA, and Maximova ID
- Subjects
- Bifidobacterium metabolism, Bisacodyl pharmacology, Bisacodyl therapeutic use, Cathartics pharmacology, Cathartics therapeutic use, Cell Membrane Permeability, Chronic Disease, Constipation microbiology, Feces microbiology, Female, Gastrointestinal Transit, Humans, Immunity, Cellular drug effects, Lactobacillus metabolism, Lymphocyte Count, Male, Ovalbumin blood, Phagocytosis, Colon immunology, Colon microbiology, Constipation immunology
- Abstract
Background: Disturbances in bowel function in chronic constipation could result in changes in the colonic flora and lead to disordered immunity and to decreased resistance to pathogenic flora., Aim: To investigate systemic immunity, the faecal flora and intestinal permeability in patients with chronic constipation, under basal conditions and following therapy with the laxative Bisacodyl., Methods: Intestinal permeability, faecal flora analysis, T- and B-lymphocyte numbers, T-cell subpopulations, lymphocyte proliferation, phagocytosis, intracellular killing of Staphylococcus aureus by neutrophils, as well as circulating levels of immunoglobulins, immune complexes and antibacterial antibodies were assessed in 57 patients with functional constipation. In 12 patients with severely delayed transit, investigations were repeated following therapy with Bisacodyl., Results: Ovalbumin concentrations, in serum, were higher in constipated patients (28.2+/-4.1 ng/ml versus 1.0+/-0.4 ng/ml, p < 0.05). Elevated counts of CD3+, CD4+, CD25+ cells, increased spontaneous proliferation of lymphocytes, elevated titres of antibodies to Escherichia coli and S. aureus, diminished counts of CD72+ B cells, diminished lymphocyte proliferation under phytohemagglutinin (PHA) stimulation and a diminished phagocytic index for both neutrophils and monocytes were found in the constipated patients. Concentrations of Bifidobacterium and Lactobacillus were significantly lower in constipated patients; potentially pathogenic bacteria and/or fungi were increased. Therapy with Bisacodyl resulted in normalisation of the faecal flora, a reduction in ovalbumin concentration and return towards normal for certain immunologic parameters., Conclusion: Constipation is associated with striking changes in the faecal flora, intestinal permeability and the systemic immune response. Relief of constipation tends to normalise these findings suggesting that these changes are secondary to, rather than a cause of, constipation.
- Published
- 2005
- Full Text
- View/download PDF
21. [Use of the Gepon immunomodulator for ulcerative colitis treatment].
- Author
-
Malakhova NS, Pichugin AV, Khalif IL, and Ataullakhanov RI
- Subjects
- Adult, Aged, CD8-Positive T-Lymphocytes cytology, Colitis, Ulcerative immunology, Female, Humans, Killer Cells, Natural cytology, Male, Middle Aged, Treatment Outcome, Adjuvants, Immunologic therapeutic use, Colitis, Ulcerative drug therapy, Peptides therapeutic use
- Abstract
The efficacy of the Gepon immunomodulator was studied in 36 patients with ulcerative colitis (UC) having distal lesions in the resistant form. Taking into account the fact that immunological abnormalities play the main role in UC pathogenesis, the drug with immunomodulatory action was used for overcoming resistance to basic anti-inflammatory drugs. The clinical and immunological reaction to the used drugs was found to be ambiguous. Most of the patients (83.3%) had clinical and endoscopic amelioration after taking Gepon and managed to overcome the resistance to basic anti-inflammatory drugs.
- Published
- 2005
22. [Impact of the impaired intestinal microflora on the course of acne vulgaris].
- Author
-
Volkova LA, Khalif IL, and Kabanova IN
- Subjects
- Acne Vulgaris diagnosis, Adolescent, Adult, Female, Humans, Male, Acne Vulgaris complications, Gastrointestinal Diseases complications, Gastrointestinal Diseases microbiology, Gastrointestinal Diseases therapy
- Abstract
The paper deals with studies of the intestinal microflora in 114 patients with acne vulgaris (94 and 20 with its papulopustular and nodulocystic forms). Sixty-one (54%) patients have either the first (21%) or second (78.7%) impaired bacterial microflora. At the same time, there are no great differences in the content of the intestinal microflora in different forms of acne. It is noted that adding intestinal microflora-correcting agents to combined therapy in patients with papulopustular acne vulgaris and verified dysbacteriosis reduces the duration of treatment by over twice and makes its duration the same as that in patients without dysbacteriosis.
- Published
- 2001
23. [Antigen-binding lymphocytes to the Mycobacterium paratuberculosis antigen in Crohn's disease and nonspecific ulcerative colitis].
- Author
-
Konovich EA, Khalif IL, Sharov VA, and Kirkin BV
- Subjects
- Epitopes immunology, Escherichia coli immunology, Humans, Intestine, Large immunology, Lymph Nodes immunology, Mesentery, Staphylococcus aureus immunology, Antigens, Bacterial immunology, Binding Sites, Antibody immunology, Colitis, Ulcerative immunology, Crohn Disease immunology, Lymphocytes immunology, Mycobacterium avium subsp. paratuberculosis immunology
- Published
- 1993
24. [Diverticulosis of the large intestine].
- Author
-
Khalif IL
- Subjects
- Combined Modality Therapy, Diagnosis, Differential, Diagnostic Errors, Diverticulum complications, Diverticulum therapy, Humans, Intestinal Diseases complications, Intestinal Diseases therapy, Diverticulum diagnosis, Intestinal Diseases diagnosis, Intestine, Large
- Published
- 1988
25. [Role of immunologic disorders in the etiology of colitis].
- Author
-
Levitan MKh, Shadrin BP, and Khalif IL
- Subjects
- Antigen-Antibody Reactions, Autoantibodies immunology, Autoantigens immunology, Colon immunology, Cytotoxicity, Immunologic, Humans, Hypersensitivity, Delayed complications, Autoimmune Diseases etiology, Colitis etiology
- Published
- 1982
26. [Immunological indices in nonspecific ulcerative colitis].
- Author
-
Levitan MKh, Shadrin BP, Khalif IL, and Mikhaĭlova TL
- Subjects
- Antigen-Antibody Reactions, Antigens, Bacterial, Autoantibodies analysis, Humans, Immunization, Immunoglobulins analysis, Intestinal Mucosa immunology, Intestine, Large immunology, Colitis, Ulcerative immunology, Immunity, Innate
- Published
- 1978
27. [Acute phase proteins in the assessment of therapy in nonspecific ulcerative colitis].
- Author
-
Kirkin BV, Rumiantsev VG, Khalif IL, and Chirkin VV
- Subjects
- Colitis, Ulcerative drug therapy, Drug Evaluation, Humans, Prednisolone therapeutic use, Prognosis, Sulfasalazine therapeutic use, Time Factors, Acute-Phase Proteins blood, Colitis, Ulcerative blood
- Published
- 1988
28. Efficiency of hemosorption in treatment of patients with ulcerative colitis.
- Author
-
Kirkin BV, Fomin SA, Ivanov AF, Eroshkina TD, Mussin II, Khalif IL, Chirkin VV, and Tabachnik AL
- Subjects
- Antigen-Antibody Complex isolation & purification, Colitis, Ulcerative blood, Colitis, Ulcerative immunology, Humans, Sulfasalazine adverse effects, Sulfasalazine therapeutic use, Toxins, Biological blood, Toxins, Biological isolation & purification, Colitis, Ulcerative therapy, Hemoperfusion
- Abstract
One hundred and seven sessions of hemosorption were performed on 77 patients with severe ulcerative colitis. Clinically, improvement was demonstrated in the reduction of the signs of intoxication in 50 to 60 per cent of patients. Combination of hemosorption and anti-inflammatory medication allowed to achieve a remission or a marked improvement determined by clinical observation or endoscopy of 39 from 52 patients with a severe, total form of the disease, whereas toxic influence of sulfasalazine was controlled and extra-intestinal complications were weakened in 8 patients from 11. Thirteen patients were operated upon due to inefficiency of therapy. Hemosorption contributed to reduction of content of protein molecules with mean molecular weight (61 per cent), phenol (73 per cent), and endotoxin of gram-negative bacteria (50 per cent). Dynamics of acute phase reactants and humoral immune factors testifies to a weak anti-inflammatory action of hemosorption. Reduced levels of plasma protein, albumin, potassium and cholesterol were corrected or spontaneously returned to normal.
- Published
- 1987
- Full Text
- View/download PDF
29. [Circulating immune complexes in patients with inflammatory diseases of the large intestine].
- Author
-
Kirkin BV, Khalif IL, Osipov SG, and Mikhaĭlova TL
- Subjects
- Adolescent, Adult, Female, Humans, Male, Middle Aged, Antigen-Antibody Complex analysis, Colitis, Ulcerative immunology, Crohn Disease immunology
- Published
- 1985
30. [Use of immunoglobulin for treating patients with nonspecific ulcerative colitis].
- Author
-
Khalif IL, Kirkin BV, Glad'ko IA, Korshunov VM, and Pinegin BV
- Subjects
- Adult, Bacteria isolation & purification, Colitis, Ulcerative microbiology, Evaluation Studies as Topic, Female, Humans, Intestines microbiology, Male, Middle Aged, Time Factors, Colitis, Ulcerative therapy, Immunization, Passive
- Abstract
The therapeutic effect of human immunoglobulins was assessed in 29 patients with nonspecific ulcerative colitis, as was their influence on intestinal flora. A 5 to 15 ml dose of immunoglobulin was administered intramuscularly every other day, 3 injections altogether. The clinical and endoscopic effect of treatment was positive in 21 patients (72.4%). Large-intestinal mucosal imprints were studied histologically in 17 patients. Inflammation subsided in 11 patients (64.7%), and glandular epithelial proliferation declined in 4 (23.5%). In the course of treatment, lactobacilli, and bifidobacteria were considerably increased in number, while opportunity organisms were decreased, a possible cause of the positive clinical effect.
- Published
- 1986
31. [Titers of antibodies against antigen O of E. coli O14 in patients with inflammatory diseases of the large intestine].
- Author
-
Shadrin BP, Khalif IL, and Turovtseva VV
- Subjects
- Antigens, Bacterial immunology, Hemagglutination Tests, Humans, O Antigens, Antibodies, Bacterial analysis, Colitis, Ulcerative immunology, Crohn Disease immunology, Escherichia coli immunology
- Abstract
The content of serum antibodies to E. coli O14 O-antigen in patients with inflammatory diseases of the large intestine was studied in the passive hemagglutination test. These antibodies were detected in 77% of patients with nonspecific ulcerous colitis and in all patients with Crohn's disease; of these, 93.5% had antibody titers of 1:32 and greater, while none of the patients with ulcerous colitis showed such titers. This study has led to the conclusion that the detection of these antibodies in high titers can be one of the criteria for the differential diagnosis of nonspecific ulcerous colitis and Crohn's disease.
- Published
- 1982
32. [Fixed immunoglobulins in nonspecific ulcerative colitis].
- Author
-
Shadrin BA, Konovich EA, and Khalif IL
- Subjects
- Adolescent, Adult, Animals, Female, Fluorescent Antibody Technique, Humans, Intestinal Mucosa immunology, Male, Middle Aged, Colitis, Ulcerative immunology, Intestine, Large immunology, Receptors, Antigen, B-Cell analysis
- Published
- 1983
33. [Natural killer cells in inflammatory diseases of the large intestine].
- Author
-
Khalif IL, Bakhov NI, Kirkin BV, Osipov SG, and Mikhaĭlova TL
- Subjects
- Adolescent, Adult, Colitis immunology, Cytotoxicity, Immunologic, Humans, Ileitis immunology, Middle Aged, Colitis, Ulcerative immunology, Crohn Disease immunology, Killer Cells, Natural immunology
- Published
- 1986
34. [Immunologic reactivity of patients with nonspecific ulcerative colitis treated with steroid hormones].
- Author
-
Kirkin BV, Khalif IL, Chirkin VV, and Mikhaĭlova TL
- Subjects
- Adolescent, Adult, Colitis, Ulcerative drug therapy, Female, Humans, Male, Middle Aged, Prednisolone therapeutic use, Colitis, Ulcerative immunology
- Published
- 1986
35. [Status of the pituitary-adrenal system in patients with non- specific ulcerative colitis].
- Author
-
Kirkin BV, Khalif IL, and Bulgakov SA
- Subjects
- Adolescent, Adrenocorticotropic Hormone blood, Adult, Humans, Hydrocortisone blood, Hydrocortisone deficiency, Middle Aged, Colitis, Ulcerative physiopathology, Pituitary-Adrenal System metabolism
- Abstract
The blood content of basal cortisol was studied in 54 patients with a total form of non-specific ulcerous colitis and in 23 of them that of ACTH. A low cortisol level was revealed in 71.4 per cent of the patients, while the level of ACTH remained unchanged. Treatment with prednisolone (1-2 mg/kg) for 6-9 weeks did not deteriorate the functional state of the hypophyseal-adrenal system. A single administration of the total daily dose of prednisolone in the morning protected the adrenal cortex from exhaustion and in some of the patients even caused increased in and normalization of the cortisol level. Rectal administration of hydrocortisone (125 mg), which was included in therapeutic scheme ensured normalization of the blood plasma cortisol level and did not cause decrease in the ACTH level.
- Published
- 1989
36. [Effect of human immunoglobulins on microflora of the large intestine in nonspecific ulcerative colitis].
- Author
-
Glad'ko IA, Pinegin BV, Korshunov VM, Khalif IL, and Kirkin BV
- Subjects
- Adult, Antibodies, Bacterial analysis, Colitis, Ulcerative microbiology, Combined Modality Therapy, Escherichia coli immunology, Evaluation Studies as Topic, Feces microbiology, Humans, Middle Aged, Time Factors, Colitis, Ulcerative therapy, Immunoglobulins administration & dosage, Intestine, Large microbiology
- Abstract
The use of commercial preparations of human immunoglobulin for the treatment of ulcerous colitis produces a positive effect on the microflora of the large intestine, contributing to the disappearance of Proteus, the lactose-negative forms of enterobacteria and the hemolytic variants of staphylococci, as well as to the increase of the amount of useful indigenous microflora (bifidobacteria and lactobacteria). The quantitative and qualitative improvement of the microflora leads, possibly, to the decrease of the intoxication of the body, improvement in the activity of the intestine and increased vitamin formation, thus giving a pronounced clinical effect and improvement in the endoscopic picture of the mucous membrane of the large intestine, peculiar for this disease.
- Published
- 1986
37. [Immunologic disorders in Crohn's disease].
- Author
-
Levitan MKh, Shadrin BP, Khalif IL, Mikhaĭlova TL, and Belinskiĭ VA
- Subjects
- Adult, Aged, Autoantibodies biosynthesis, Female, Humans, Intestine, Large immunology, Lymphopenia etiology, Male, Middle Aged, T-Lymphocytes immunology, Autoimmune Diseases immunology, Crohn Disease immunology
- Published
- 1979
38. [Immunologic disorders in nonspecific inflammatory diseases of the large intestine].
- Author
-
Kirkin BV, Konovich EA, Khalif IL, Osipov CG, and Mikhaĭlova TL
- Subjects
- Antigen-Antibody Complex immunology, Basement Membrane immunology, Colon immunology, Humans, Immunoglobulin G immunology, Immunoglobulin M immunology, Colitis, Ulcerative etiology, Crohn Disease etiology, Immune Complex Diseases etiology
- Published
- 1986
39. [IgG, IgM, IgA, secretory IgA and the complement components C3, C4 and C9 in the large intestine in nonspecific ulcerative colitis and Crohn disease].
- Author
-
Konovich EA, Kirkin BV, and Khalif IL
- Subjects
- Epithelium immunology, Humans, Immunologic Tests, Intestinal Mucosa blood supply, Intestinal Mucosa immunology, Colitis, Ulcerative immunology, Complement System Proteins analysis, Crohn Disease immunology, Immunoglobulins analysis, Intestine, Large immunology
- Abstract
The immunohistological study of the large intestines excised from 20 patients with ulcerous colitis and Crohn's disease was made with the use of the indirect immunofluorescence test. A considerable increase in the number of IgG immunocytes has been noted in the lamina propria of the mucous membrane, especially in infiltrations around ulcers. In cases of a highly active inflammatory process accompanied by the pronounced destruction of the epithelium, IgG and C3, C4, C9 were detected in the epithelium of crypts and in blood vessels of the mucous membrane and the submucosa. One-third of the patients showed a decrease in the number of crypts with secretory and serum IgA. The authors suggest that immune complexes take part in maintaining the chronic inflammatory process.
- Published
- 1987
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.